Your browser doesn't support javascript.
loading
Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation.
Tanzi, Matteo; Montini, Enrica; Rumolo, Agnese; Moretta, Antonia; Comoli, Patrizia; Acquafredda, Gloria; Rotella, Jessica; Taurino, Gloria; Compagno, Francesca; Cave, Francesco Delle; Perotti, Cesare; Marseglia, Gian Luigi; Zecca, Marco; Montagna, Daniela.
Affiliation
  • Tanzi M; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Montini E; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Rumolo A; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Moretta A; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Comoli P; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Acquafredda G; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Rotella J; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Taurino G; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Compagno F; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Cave FD; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Perotti C; Immunohaematology and Transfusion Medicine Service (SIMT), Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Marseglia GL; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Sciences Clinic-Surgical, Diagnostic and Pediatric, University of Pavia, Pavia, Italy.
  • Zecca M; Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Montagna D; Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Sciences Clinic-Surgical, Diagnostic and Pediatric, University of Pavia, Pavia, Italy. Electronic address: d.montagna@smatteo.pv.it.
Cytotherapy ; 26(8): 878-889, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38703155
ABSTRACT
BACKGROUND

AIMS:

Somatic cell therapy based on the infusion of donor-derived cytotoxic T lymphocytes (CTL) able to recognize patients' leukemia blasts (LB) is a promising approach to control leukemia relapse after allogeneic HSCT. The success of this approach strongly depends on the ex vivo generation of high-quality donor-derived anti-leukemia CTL in compliance with Good Manufacturing Practices (GMP). We previously described a procedure for generating large numbers of donor-derived anti-leukemia CTL through stimulation of CD8-enriched lymphocytes with dendritic cells (DCs) pulsed with apoptotic LB in the presence of interleukin (IL)-12, IL-7 and IL-15. Here we report that the use of IFN-DC and the addition of IFNα2b during the priming phase significantly improve the generation of an efficient anti-leukemia T cells response in vitro.

METHODS:

Using this approach, 20 high-risk pediatric patients given haploidentical HSCT for high-risk acute leukemia were enrolled and 51 batches of advanced therapy medical products (ATMP), anti-leukemia CTL, were produced.

RESULTS:

Quality controls demonstrated that all batches were sterile, free of mycoplasma and conformed to acceptable endotoxin levels. Genotype analysis confirmed the molecular identity of the ATMP based on the starting biological material used for their production. The majority of ATMP were CD3+/CD8+ cells, with a memory/terminal activated phenotype, including T-central memory populations. ATMP were viable after thawing, and most ATMP batches displayed efficient capacity to lyse patients' LB and to secrete interferon-γ and tumor necrosis factor-α.

CONCLUSIONS:

These results demonstrated that our protocol is highly reproducible and allows the generation of large numbers of immunologically safe and functional anti-leukemia CTL with a high level of standardization.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes, Cytotoxic / Leukemia / Immunotherapy, Adoptive / Hematopoietic Stem Cell Transplantation Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Cytotherapy Journal subject: TERAPEUTICA Year: 2024 Type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes, Cytotoxic / Leukemia / Immunotherapy, Adoptive / Hematopoietic Stem Cell Transplantation Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Cytotherapy Journal subject: TERAPEUTICA Year: 2024 Type: Article Affiliation country: Italy